ON
🔍
← Back to feed
United StatesPolitics11 days ago

STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices

The article discusses the differing approaches taken by European countries regarding drug pricing, highlighting the U.K.'s move toward more industry-friendly policies and Germany's proposal to reduce healthcare spending and increase pharmaceutical fees. The piece notes the impact of these decisions on pharmaceutical companies and patients, as well as the role of external influences such as the U.S.

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

LONDON — In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting pharma companies and patients across the continent — and testing the influence of the U.S.

In the U.K., after a pressure campaign from both pharma companies and the Trump administration, the government has adopted more industry-friendly policies while also simply promising to spend more on medicines.

Germany, another of the continent’s biggest markets, is headed in the opposite direction. Facing growing deficits in its health budget, the government has proposed moves that would cut spending and increase the fees the industry has to pay.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Read the full article at STAT News →
Source document: U.K. Government Policies on Drug Pricing

1 reports

STAT NewsIndependentCenter11 days ago
STAT+: As the U.S. looks on, European countries feel growing pressure on drug prices

The article discusses the differing approaches taken by European countries regarding drug pricing, highlighting the U.K.'s move toward more industry-friendly policies and Germany's proposal to reduce healthcare spending and increase pharmaceutical fees. The piece notes the impact of these decisions on pharmaceutical companies and patients, as well as the role of external influences such as the U.S.

Bias read (Center): The article presents information without overtly favoring one side, providing a balanced overview of the contrasting policies in the U.K. and Germany. It does not employ loaded language or selectively present sources to support a particular viewpoint.

Official sources cited

  • government U.K. Government Policies on Drug Pricing
  • government German Health Budget Deficits and Proposed Measures

Go to the primary sources (2)

The official sources this coverage is built on. Read them directly to bypass framing.

  • governmentU.K. Government Policies on Drug Pricing
  • governmentGerman Health Budget Deficits and Proposed Measures